- Status:
- Red
- Decision Date:
- September 2018
Comments
RED:
- NICE TA538 - for treating high-risk neuroblastoma. (Decision date - September 2018).
NHS England drug. To be used in line with NHSE commissioning intentions.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again